Cancer diagnosis & prognosis最新文献_第7页

Immunotherapeutic Innovations in Clear Cell Renal Cell Carcinoma: Current Strategies and Future Directions. 透明细胞肾细胞癌的免疫治疗创新：当前策略与未来方向。

Cancer diagnosis & prognosis Pub Date : 2024-09-01 DOI: 10.21873/cdp.10363

Stefania Chipuc, Haineala Bogdan, Dragos Serban, Dumitru Cristinel Badiu, Anca Zgura, Rodica Anghel

{"title":"Immunotherapeutic Innovations in Clear Cell Renal Cell Carcinoma: Current Strategies and Future Directions.","authors":"Stefania Chipuc, Haineala Bogdan, Dragos Serban, Dumitru Cristinel Badiu, Anca Zgura, Rodica Anghel","doi":"10.21873/cdp.10363","DOIUrl":"10.21873/cdp.10363","url":null,"abstract":"Approximatively 80% of kidney cancers globally are clear cell kidney cancers (ccRCCs), with 80% of these malignancies featuring an inactivating mutation of the Von Hippel-Lindau gene. This genetic alteration leads to the stabilization of hypoxia inducible factors 1 and 2 alpha (HIF 1 and 2α), resulting in the over-expression of target genes such as vascular endothelial growth factor (VEGF), which is crucial for angiogenesis. As a result, ccRCCs are highly vascularized and serve as models for anti-angiogenic treatments (AAT). Current AAT therapies comprise antibodies targeting VEGFs, tyrosine kinase inhibitors (TKi) (Sunitinib) that target neo-angiogenesis receptors, and competitive inhibitor receptors (Aflibercept) that trap VEGFA and PlGF. The over-expression of VEGF and related members such as VEGFC significantly influences angiogenesis, lymph-angiogenesis, and immune tolerance. This has resulted in the approval of various immune checkpoint inhibitors (known as anti-PD-1, anti-PD-L1, and anti-CTLA-4) as viable treatment options for kidney cancer. Despite these advances, ccRCC remains challenging to treat adequately. Thus, future research is imperative to better understand the biology and pathophysiology of RCC, the tumor microenvironment, and mechanisms of resistance, with the aim of developing new therapies.","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":"4 5","pages":"558-562"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11372689/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142141891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Putative Dual Roles of Bone Morphogenetic Protein 8B (BMP8B) in Disease Progression of Gastric Cancer. 骨形态发生蛋白 8B (BMP8B) 在胃癌疾病进展中的推定双重作用

Cancer diagnosis & prognosis Pub Date : 2024-09-01 DOI: 10.21873/cdp.10365

Zhiwei Sun, Shuo Cai, Xiangyi Liu, Wen G Jiang, Lin Ye

{"title":"Putative Dual Roles of Bone Morphogenetic Protein 8B (BMP8B) in Disease Progression of Gastric Cancer.","authors":"Zhiwei Sun, Shuo Cai, Xiangyi Liu, Wen G Jiang, Lin Ye","doi":"10.21873/cdp.10365","DOIUrl":"10.21873/cdp.10365","url":null,"abstract":"Background/aim: Increased expression of bone morphogenetic protein 8B (BMP8B) in bone marrow and primary tumors of patients with gastric cancer (GC) is associated with disease progression and poor prognosis. However, a reduced expression has also been seen in GCs due to histone acetylation. This study aimed to evaluate BMP8B transcript levels in a large GC cohort and its impact on cellular functions.Materials and methods: BMP8B transcripts were determined in 319 gastric tumors and compared with 182 adjacent normal tissues using real time PCR, with a further analysis conducted in the TCGA database. Kaplan-Meier plotter analysis was performed to evaluate the correlation between BMP8B and prognosis of the disease. BMP8B knockdown model was employed to determine the effect of BMP8B on the function of GC cells (HGC27).Results: BMP8B mRNA levels were significantly up-regulated in the GC tissues compared with adjacent normal tissues in both TCGA database and our own database from Beijing Cancer Hospital, and high BMP8B expression was associated with poor prognosis. BMP8B is most likely to be involved in the differentiation of GC. Poorly differentiated GC samples presented a significantly reduced BMP8B expression in relation to well-differentiated and moderately differentiated GC. BMP8B knockdown inhibited proliferation of GC cells, while promoted invasion and migration of cancer cells.Conclusion: BMP8B was reduced in GCs, whereas higher BMP8B expression was associated with poor prognosis. BMP8B knockdown inhibited proliferation of GC cells, and promoted invasion and migration. Our results suggest that BMP8B plays dual roles in GC.","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":"4 5","pages":"567-578"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11372696/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142141896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Atezolizumab Plus Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma: Real-life Experience from a Single Tertiary Centre in Spain and ALBI Score as a Survival Prognostic Factor. 阿特珠单抗联合贝伐单抗治疗无法切除的肝细胞癌：西班牙单个三级中心的实际经验以及作为生存预后因素的 ALBI 评分。

Cancer diagnosis & prognosis Pub Date : 2024-09-01 DOI: 10.21873/cdp.10373

María Pilar Ballester, Carlos Abril, Víctor Merino, Manuel Alós, Gloria Segarra, Joan Tosca, Cristina Montón, Nuria Casasus, Paloma Lluch

{"title":"Atezolizumab Plus Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma: Real-life Experience from a Single Tertiary Centre in Spain and ALBI Score as a Survival Prognostic Factor.","authors":"María Pilar Ballester, Carlos Abril, Víctor Merino, Manuel Alós, Gloria Segarra, Joan Tosca, Cristina Montón, Nuria Casasus, Paloma Lluch","doi":"10.21873/cdp.10373","DOIUrl":"10.21873/cdp.10373","url":null,"abstract":"Background/aim: Atezolizumab/bevacizumab (atez/bev) has been established as first-line systemic treatment for hepatocellular carcinoma (HCC). However, concerns regarding safety and efficacy have been raised, and no biomarkers to predict response have yet been identified. We aimed to evaluate the real-life experience of atez/bev in a Spanish tertiary hospital and identify factors associated with overall survival (OS).Patients and methods: A prospective study of consecutive patients with HCC treated with atez/bev was conducted from December 2020 to December 2022. Efficacy was assessed through OS and progression-free survival (PFS), whereas safety was evaluated based on adverse events (AE). Twenty-three patients were included; 91% were males with a mean of 70 years. Thirteen patients were classified as having BCLC-C.Results: The median treatment duration was 126 days (range=567). Median OS was 381 days (95%CI=205-557) with a cumulative probability of death of 13%, 30%, and 49% at 3, 6 and 12-month follow-up, respectively. The only factor associated with OS was the ALBI score (HR=5.03; 95%CI=1.3-19.1), which showed an AUROC of 0.906 (95%CI=0.78-1.00) for the risk of death at 18 months follow up. Median PFS was 141 days (95%CI=110-172). Twenty (86.9%) patients experienced AE, which in nine (39.1%) cases led to the definitive discontinuation of the treatment, four of them (17.4%) due to an AE grade 5.Conclusion: The initial experience with atez/bev at our center demonstrated poorer outcomes compared to the original trial (IMbrave150). A careful assessment of the ALBI score may serve as a crucial factor in the selection of systemic treatment for patients with HCC.","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":"4 5","pages":"623-630"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11372697/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142141883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diagnostic Impacts of Aldehyde Dehydrogenase 2 Genetic Variants on Hepatocellular Carcinoma Susceptibility. 醛脱氢酶 2 基因变异对肝细胞癌易感性的诊断影响

Cancer diagnosis & prognosis Pub Date : 2024-09-01 DOI: 10.21873/cdp.10366

Yu-Ting Chin, Ming-Hsien Wu, Hou-Yu Shih, Chia-Wen Tsai, Jen-Sheng Pei, Tao-Wei Ke, Yun-Chi Wang, Yi-Chih Hung, Jaw-Chyun Chen, DA-Tian Bau, Wen-Shin Chang

{"title":"Diagnostic Impacts of Aldehyde Dehydrogenase 2 Genetic Variants on Hepatocellular Carcinoma Susceptibility.","authors":"Yu-Ting Chin, Ming-Hsien Wu, Hou-Yu Shih, Chia-Wen Tsai, Jen-Sheng Pei, Tao-Wei Ke, Yun-Chi Wang, Yi-Chih Hung, Jaw-Chyun Chen, DA-Tian Bau, Wen-Shin Chang","doi":"10.21873/cdp.10366","DOIUrl":"10.21873/cdp.10366","url":null,"abstract":"Background/aim: The role of alcohol consumption and aldehyde dehydrogenase 2 (ALDH2) genotype in hepatocellular carcinoma (HCC) development remains uncertain.Materials and methods: We conducted genotyping of the ALDH2 rs671 single nucleotide polymorphism in 298 patients with HCC and 889 non-cancerous healthy controls. We assessed associations stratified by sex and alcohol consumption status.Results: Distribution of ALDH2 rs671 variant genotypes differed significantly between HCC patients and controls (ptrend=0.0311). Logistic regression analyses indicated that compared to the wild-type GG genotype, the heterozygous variant AG genotype and homozygous variant AA genotype conferred 1.22- and 1.77-fold increases in HCC risk (p=0.1794 and 0.0150, respectively). Allelic frequency analysis showed that the A allele was associated with a 1.29-fold increased HCC risk (p=0.0123). Additionally, AA genotype carriers had significantly higher HCC risk than GG genotype carriers among males (p=0.0145) and non-alcohol drinkers (p<0.001).Conclusion: HCC risk is influenced by ALDH2 genotype, with effects modified by sex and alcohol consumption. Particularly, individuals with the ALDH2 rs671 AA genotype should avoid alcohol consumption, especially males.","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":"4 5","pages":"579-585"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11372694/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142141887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Mayo Adhesive Probability Score as a Predictor of Postoperative Renal Function in Robot-assisted Partial Nephrectomy. 梅奥粘连概率评分作为机器人辅助肾部分切除术术后肾功能的预测指标。

Cancer diagnosis & prognosis Pub Date : 2024-09-01 DOI: 10.21873/cdp.10377

Hiroshi Matsuzaki, Kazuna Tsubouchi, Y U Okabe, Takeshi Miyazaki, Naotaka Gunge, Kosuke Tominaga, Yuichiro Fukuhara, Masahiro Tachibana, Chizuru Nakagawa, Fumihiro Yamazaki, Nobuyuki Nakamura, Nobuhiro Haga

{"title":"The Mayo Adhesive Probability Score as a Predictor of Postoperative Renal Function in Robot-assisted Partial Nephrectomy.","authors":"Hiroshi Matsuzaki, Kazuna Tsubouchi, Y U Okabe, Takeshi Miyazaki, Naotaka Gunge, Kosuke Tominaga, Yuichiro Fukuhara, Masahiro Tachibana, Chizuru Nakagawa, Fumihiro Yamazaki, Nobuyuki Nakamura, Nobuhiro Haga","doi":"10.21873/cdp.10377","DOIUrl":"10.21873/cdp.10377","url":null,"abstract":"Background/aim: The aim of this study was to evaluate the Mayo Adhesive Probability (MAP) score as a predictor of split renal function deterioration after robot-assisted partial nephrectomy (RAPN).Patients and methods: A total of 30 patients who underwent RAPN were identified retrospectively. The parameters evaluated included patient characteristics, tumor diameter, MAP score, warm ischemic time (WIT), and renal function. Split renal function was evaluated using Tc-99m DTPA renal scintigraphy before and six months after surgery. Univariate and multivariate logistic regression analyses were performed.Results: Nine patients (30.0%) showed more than 90% preservation of split renal function on the operated side. The MAP score (p=0.015), cT1b tumor (p=0.0002), and WIT (p=0.044) were associated with preservation of split renal function six months after surgery on univariate analysis. The MAP score was the strongest predictor of preservation of split renal function six months after surgery on multivariable analysis (p=0.007). On receiver-operating characteristic (ROC) curve analysis, the MAP score (cutoff value 3.0; p=0.01) was a significant predictor of split renal function six months after surgery.Conclusion: The MAP score was significantly associated with postoperative split renal function six months after RAPN on the operated kidney side. The MAP score is useful for predicting split renal function after RAPN.","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":"4 5","pages":"652-657"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11372686/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142141899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association of Oncotype-DX HER2 Single Gene Score With HER2 Expression Assessed by Immunohistochemistry in HER2-low Breast Cancer. Oncotype-DX HER2 单基因评分与免疫组化评估 HER2 低表达乳腺癌中 HER2 表达的关系

Cancer diagnosis & prognosis Pub Date : 2024-09-01 DOI: 10.21873/cdp.10370

George Douganiotis, Loukas Kontovinis, Thomas Zarampoukas, Ioannis Natsiopoulos, Konstantinos Papazisis

{"title":"Association of Oncotype-DX HER2 Single Gene Score With HER2 Expression Assessed by Immunohistochemistry in HER2-low Breast Cancer.","authors":"George Douganiotis, Loukas Kontovinis, Thomas Zarampoukas, Ioannis Natsiopoulos, Konstantinos Papazisis","doi":"10.21873/cdp.10370","DOIUrl":"10.21873/cdp.10370","url":null,"abstract":"Background/aim: \"HER2-low\" is an emerging subtype of breast cancer, with a documented role in predicting response to treatment with novel antibody-drug conjugates. It is defined based on immunohistochemistry, but increasing evidence is challenging this approach as appropriate for identifying the HER2-low subgroup, due to both interobserver variability and limitations of the method itself.Patients and methods: We retrospectively analyzed data from 430 patients from our departmental databases who had been subjected to an Oncotype-DX score and assessed the correlation of the Oncotype-DX HER2 single-gene score with the HER2 expression on immunohistochemistry. The Oncotype-DX Recurrence Score was also evaluated in the HER2-0 versus HER2-low subgroups.Results: The HER2 single-gene score was found to accurately correlate with the HER2 result on immunohistochemistry, with a statistically significant difference both between HER2-0 and HER2 +1 tumors (p<0.0001), as well as between HER2 +1 and +2 tumors (p<0.0001). There was no statistically significant difference in the recurrence score between the HER2-0 and the HER2-low subgroups.Conclusion: Oncotype-DX single-gene scores for HER2 are a potential surrogate marker for assessing the precise HER2 status, with better reproducibility and less interobserver variance compared to immunohistochemistry. The use of rt-PCR emerges as an alternative method of assessment of the HER2-low subgroup.","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":"4 5","pages":"605-610"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11372695/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142141876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association of PARP1 Expression Levels and Clinical Parameters in Different Leukemic Subtypes With BCR::ABL1 p190+ Translocation. 带有 BCR::ABL1 p190+ 转位的不同白血病亚型中 PARP1 表达水平与临床参数的关系

Cancer diagnosis & prognosis Pub Date : 2024-09-01 DOI: 10.21873/cdp.10368

Guilherme Passos DE Morais, Caio Bezerra Machado, Beatriz Maria Dias Nogueira, Flávia Melo Cunha DE Pinho Pessoa, Deivide DE Sousa Oliveira, Rodrigo Monteiro Ribeiro, Jean Breno Silveira DA Silva, Aline Damasceno Seabra, Fernando Augusto Rodrigues Mello Júnior, Rommel Rodriguez Burbano, André Salim Khayat, Manoel Odorico DE Moraes Filho, Maria Elisabete Amaral DE Moraes, Caroline Aquino Moreira-Nunes

{"title":"Association of PARP1 Expression Levels and Clinical Parameters in Different Leukemic Subtypes With BCR::ABL1 p190+ Translocation.","authors":"Guilherme Passos DE Morais, Caio Bezerra Machado, Beatriz Maria Dias Nogueira, Flávia Melo Cunha DE Pinho Pessoa, Deivide DE Sousa Oliveira, Rodrigo Monteiro Ribeiro, Jean Breno Silveira DA Silva, Aline Damasceno Seabra, Fernando Augusto Rodrigues Mello Júnior, Rommel Rodriguez Burbano, André Salim Khayat, Manoel Odorico DE Moraes Filho, Maria Elisabete Amaral DE Moraes, Caroline Aquino Moreira-Nunes","doi":"10.21873/cdp.10368","DOIUrl":"10.21873/cdp.10368","url":null,"abstract":"Background/aim: Although the reciprocal translocation t(9;22)(q34;q11) is a hallmark of chronic myeloid leukemia (CML), it is also present in acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). Depending on the gene's breakpoint, it is possible to obtain three isoforms, among which p190 stands out for the poor prognosis it induces whenever it appears. Due to the genomic instability induced by BCR::ABL1, it is proposed to expand the applicability of poly-ADP-ribose polymerase-1 (PARP1) and its inhibitors in hematological neoplasms.Materials and methods: We measured the expression levels of PARP1 by quantitative real-time PCR (qPCR) using TaqMan®, correlating its expression with BCR::ABL1 p190+, to evaluate its influence in the clinic of adult patients.Results: We found that PARP1 is expressed differently in ALL, AML and CML and that p190 transcripts do not follow a linear pattern in these populations. We also found that PARP1 expression is not correlated with age, white blood cell and the amount of p190 transcripts.Conclusion: Despite the lack of statistical correlation between the variables analyzed, the role of PARP1 in BCR::ABL1 leukemia cannot be ruled out, given the instability profile promoted by this translocation. Finally, further studies involving a larger sample of patients are needed, as well as investigations into other molecular pathways that may impact on the pathogenesis of different BCR::ABL1 leukemic subtypes.","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":"4 5","pages":"592-598"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11372699/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142141882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of Local Recurrence Between LEN-TACE and TACE for Hepatocellular Carcinoma According to Lipiodol Accumulation. 根据脂肪碘累积情况比较 LEN-TACE 和 TACE 治疗肝细胞癌的局部复发率

Cancer diagnosis & prognosis Pub Date : 2024-09-01 DOI: 10.21873/cdp.10371

Toru Ishikawa, Ryo Sato, Ryo Jimbo, Yuji Kobayashi, Toshifumi Sato, Akito Iwanaga, Tomoe Sano, Junji Yokoyama, Terasu Honma

{"title":"Comparison of Local Recurrence Between LEN-TACE and TACE for Hepatocellular Carcinoma According to Lipiodol Accumulation.","authors":"Toru Ishikawa, Ryo Sato, Ryo Jimbo, Yuji Kobayashi, Toshifumi Sato, Akito Iwanaga, Tomoe Sano, Junji Yokoyama, Terasu Honma","doi":"10.21873/cdp.10371","DOIUrl":"10.21873/cdp.10371","url":null,"abstract":"Background/aim: Transarterial chemoembolization (TACE) is the standard treatment for patients with hepatocellular carcinoma in the intermediate stage; however, with advances in systemic therapy, the indications for TACE have gained significance. While lenvatinib (LEN)-TACE offers the potential for good outcomes, local recurrence has not yet been adequately investigated. Therefore, this study investigated local recurrence factors for each type of TACE, focusing on the lipiodol (Lip) value in LEN-TACE and conventional TACE.Patients and methods: Fifty patients (50 nodes) with hepatocellular carcinoma and a tumor size <7 cm who underwent LEN-TACE or TACE between January 2022 and June 2023 were included in this study to investigate local recurrence and its influencing factors.Results: The local recurrence rate after LEN-TACE was 5.6% at 6 months and 11.5% at 12 months, whereas those after TACE were 6.4% at 6 months and 13.2% at 12 months (p=0.028). There were no significant differences in local recurrence rates according to background liver factors, alpha-fetoprotein (AFP), des-γ-carboxy prothrombin (DCP) values, sex, age, and albumin-bilirubin (ALBI) score. Lipiodol (Lip) values immediately after LEN-TACE were significantly higher than those after TACE alone (p=0.021). Multivariate analysis showed that LEN-TACE had a recurrence hazard ratio of 0.184.Conclusion: LEN-TACE provided good local tumor control. Local recurrence factors included LEN pretreatment, and Lip CT values were higher immediately after LEN-TACE. Thus, LEN-TACE after upfront LEN administration may increase the effectiveness of TACE.","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":"4 5","pages":"611-616"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11372692/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142141885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Imaging Transgenic Nude Mice Expressing Spectrally-distinct Fluorescent Reporters Emitting From Blue to Far Red Light With One Instrument With Single-nanometer-tuning of Laser-excitation Fluorescence. 用一台仪器对表达从蓝光到远红光的光谱不同的荧光报告器的转基因裸鼠进行成像，并对激光激发荧光进行单纳米调谐。

Cancer diagnosis & prognosis Pub Date : 2024-09-01 DOI: 10.21873/cdp.10364

Kohei Mizuta, Jose Reynoso, Sean Gallagher, April Wang, Neil Chang, Sei Morinaga, Motokazu Sato, Byung Mo Kang, Robert M Hoffman

{"title":"Imaging Transgenic Nude Mice Expressing Spectrally-distinct Fluorescent Reporters Emitting From Blue to Far Red Light With One Instrument With Single-nanometer-tuning of Laser-excitation Fluorescence.","authors":"Kohei Mizuta, Jose Reynoso, Sean Gallagher, April Wang, Neil Chang, Sei Morinaga, Motokazu Sato, Byung Mo Kang, Robert M Hoffman","doi":"10.21873/cdp.10364","DOIUrl":"10.21873/cdp.10364","url":null,"abstract":"Background/aim: Transgenic nude mice expressing green fluorescent protein (GFP), red fluorescent protein (RFP), or cyan fluorescent protein (CFP) were previously developed by our laboratory, AntiCancer Inc. In the present study, we demonstrate imaging of the GFP, RFP, or CFP nude mice with single-nanometer-tuning laser fluorescence excitation with a single instrument.Materials and methods: Female transgenic C57/B6 nude GFP, RFP, and CFP mice aged six weeks were used. The images were obtained using the UVP Biospectrum Advanced system (Analytik Jena US LLC) with excitation at 480 nm and peak emission at 513 nm for GFP; 520 nm and 605 nm, respectively, for RFP; and 405 nm and 480 nm, respectively, for CFP.Results: For each color transgenic fluorescent mouse, images without background could be obtained individually with the UVP Biospectrum Advanced system.Conclusion: Using a single instrument, brilliant and well-defined images of GFP, RFP, and CFP mice were obtained with single-nanometer-tuning laser fluorescence excitation. This imaging system will be used in future studies to analyze cancer cells in the colored mice that are spectrally distinct in order to determine how stromal cells and cancer interact in the tumor microenvironment.","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":"4 5","pages":"563-566"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11372684/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142141890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Predictors of Progression to Castration-resistant Prostate Cancer After Radical Prostatectomy in High-risk Prostate Cancer Patients. 高危前列腺癌患者根治性前列腺切除术后发展为阉割抗性前列腺癌的预测因素。

Cancer diagnosis & prognosis Pub Date : 2024-09-01 DOI: 10.21873/cdp.10376

Takato Nishino, Shinya Yamamoto, Noboru Numao, Yoshinobu Komai, Tomohiko Oguchi, Yosuke Yasuda, Ryo Fujiwara, Takeshi Yuasa, Junji Yonese

{"title":"Predictors of Progression to Castration-resistant Prostate Cancer After Radical Prostatectomy in High-risk Prostate Cancer Patients.","authors":"Takato Nishino, Shinya Yamamoto, Noboru Numao, Yoshinobu Komai, Tomohiko Oguchi, Yosuke Yasuda, Ryo Fujiwara, Takeshi Yuasa, Junji Yonese","doi":"10.21873/cdp.10376","DOIUrl":"10.21873/cdp.10376","url":null,"abstract":"Background/aim: To examine the specific time frame and identify associated risk factors from commencement of hormonal therapy to the onset of castration-resistant prostate cancer among patients who have developed biochemical recurrence following radical prostatectomy.Patients and methods: We retrospectively reviewed the records of 92 patients who developed biochemical recurrence and received hormonal therapy as initial salvage treatment after radical prostatectomy for high-risk localized prostate cancer from 2005 to 2021. The castration-resistant prostate cancer-free survival rates from the commencement of salvage hormonal therapy were analyzed using log-rank methods. Cox proportional hazard regression was performed to analyze the risk factors associated with acquiring castration resistance. The patients were stratified based on those risk factors.Results: During a median follow-up duration of 57 months, 24 (26.1%) patients developed castration-resistant prostate cancer. The 5- and 10-year castration-resistant prostate cancer-free survival rates were 73.6% and 54.5%, respectively. A multivariate analysis showed that Grade Group of 5 and prostate-specific antigen doubling time at biochemical recurrence of ≤3 months were independent predictors of castration-resistant prostate cancer. The 5-year castration-resistant prostate cancer-free survival rates in the low- and high-risk groups, stratified according to the aforementioned factors, were 85.4% and 47.6%, respectively.Conclusion: Patients in high Grade Group and short prostate-specific antigen doubling time after radical prostatectomy are more likely to develop resistance to salvage hormonal therapy.","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":"4 5","pages":"646-651"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11372693/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142141894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0